Coactivation of Two Different G Protein-coupled Receptors is Essential for ADP-induced Platelet Aggregation

Overview

Journal Proc Natl Acad Sci U S A

Specialty Science

Date 1998 Jul 8

PMID 9653141

Citations 138

Authors

J Jin

S P Kunapuli

Affiliations

Soon will be listed here.

Abstract

ADP is an important platelet agonist causing shape change and aggregation required for physiological hemostasis. We recently demonstrated the existence of two distinct G protein-coupled ADP receptors on platelets, one coupled to phospholipase C, P2Y1, and the other to inhibition of adenylyl cyclase, P2TAC. In this study, using specific antagonists for these two receptors, we demonstrated that concomitant intracellular signaling from both the P2TAC and P2Y1 receptors is essential for ADP-induced platelet aggregation. Inhibition of signaling through either receptor, by specific antagonists, is sufficient to block ADP-induced platelet aggregation. Furthermore, signaling through the P2TAC receptor could be replaced by activation of alpha2A-adrenergic receptors. On the other hand, activation of serotonin receptors supplements signaling through the P2Y1 receptor. Moreover, this mechanism of ADP-induced platelet aggregation could be mimicked by coactivation of two non-ADP receptors coupled to Gi and Gq, neither of which can cause platelet aggregation by itself. We propose that platelet aggregation results from concomitant signaling from both the Gi and Gq, a mechanism by which G protein-coupled receptors elicit a physiological response.

Citing Articles

Purinergic P2Y and P2Y receptors control enteric nervous system activity through neuro-glia-macrophage crosstalk.

Hendler B, McClain J, Zilli A, Seguella L, Gulbransen B Purinergic Signal. 2024; .

PMID: 39612055 DOI: 10.1007/s11302-024-10060-9.

Personalized Approaches to Cardiovascular Disease: Insights into FDA-Approved Interventions and Clinical Pharmacogenetics.

Raoufinia R, Rahimi H, Abbaszadeh M, Gholoobi A, Saburi E, Fakoor F Curr Pharm Des. 2024; 30(21):1667-1680.

PMID: 38738725 DOI: 10.2174/0113816128309440240427102903.

Current Strategies to Guide the Antiplatelet Therapy in Acute Coronary Syndromes.

Russo I, Griffith Brookles C, Barale C, Melchionda E, Mousavi A, Biole C Int J Mol Sci. 2024; 25(7).

PMID: 38612792 PMC: 11011739. DOI: 10.3390/ijms25073981.

Blood oxygen regulation via P2Y12R expressed in the carotid body.

Iring A, Baranyi M, Iring-Varga B, Mut-Arbona P, Gal Z, Nagy D Respir Res. 2024; 25(1):61.

PMID: 38281036 PMC: 10821555. DOI: 10.1186/s12931-024-02680-x.

Purinergic signaling in the battlefield of viral infections.

Carvalho-Barbosa N, Zeidler J, Savio L, Coutinho-Silva R Purinergic Signal. 2023; .

PMID: 38038801 DOI: 10.1007/s11302-023-09981-8.

References

Steen V, Holmsen H, Aarbakke G . The platelet-stimulating effect of adrenaline through alpha 2-adrenergic receptors requires simultaneous activation by a true stimulatory platelet agonist. Evidence that adrenaline per se does not induce human platelet activation in vitro. Thromb Haemost. 1993; 70(3):506-13. View

GAARDER A, JONSEN J, LALAND S, HELLEM A, Owren P . Adenosine diphosphate in red cells as a factor in the adhesiveness of human blood platelets. Nature. 1961; 192:531-2. DOI: 10.1038/192531a0. View

Hourani S, Hall D . Receptors for ADP on human blood platelets. Trends Pharmacol Sci. 1994; 15(4):103-8. DOI: 10.1016/0165-6147(94)90045-0. View

Hirata T, Kakizuka A, Ushikubi F, Fuse I, Okuma M, Narumiya S . Arg60 to Leu mutation of the human thromboxane A2 receptor in a dominantly inherited bleeding disorder. J Clin Invest. 1994; 94(4):1662-7. PMC: 295328. DOI: 10.1172/JCI117510. View

Fredholm B, Abbracchio M, Burnstock G, Daly J, Harden T, Jacobson K . Nomenclature and classification of purinoceptors. Pharmacol Rev. 1994; 46(2):143-56. PMC: 4976594. View

Nurden P, Savi P, Heilmann E, Bihour C, Herbert J, Maffrand J . An inherited bleeding disorder linked to a defective interaction between ADP and its receptor on platelets. Its influence on glycoprotein IIb-IIIa complex function. J Clin Invest. 1995; 95(4):1612-22. PMC: 295660. DOI: 10.1172/JCI117835. View

Moolenaar W . Lysophosphatidic acid, a multifunctional phospholipid messenger. J Biol Chem. 1995; 270(22):12949-52. DOI: 10.1074/jbc.270.22.12949. View

Humphries R, Robertson M, Leff P . A novel series of P2T purinoceptor antagonists: definition of the role of ADP in arterial thrombosis. Trends Pharmacol Sci. 1995; 16(6):179-81. DOI: 10.1016/s0165-6147(00)89018-5. View

Salzman E . Cyclic AMP and platelet function. N Engl J Med. 1972; 286(7):358-63. DOI: 10.1056/NEJM197202172860708. View

10.

Macfarlane D, MILLS D . The effects of ATP on platelets: evidence against the central role of released ADP in primary aggregation. Blood. 1975; 46(3):309-20. View

11.

Cusack N, Hourani S . Adenosine 5-diphosphate antagonists and human platelets: no evidence that aggregation and inhibition of stimulated adenylate cyclase are mediated by different receptors. Br J Pharmacol. 1982; 76(1):221-7. PMC: 2068757. DOI: 10.1111/j.1476-5381.1982.tb09210.x. View

12.

Cusack N, Hourani S . Competitive inhibition by adenosine 5'-triphosphate of the actions on human platelets of 2-chloroadenosine 5'-diphosphate, 2-azidoadenosine 5'-diphosphate and 2-methylthioadenosine 5'-diphosphate. Br J Pharmacol. 1982; 77(2):329-33. PMC: 2044602. DOI: 10.1111/j.1476-5381.1982.tb09302.x. View

13.

Seuwen K, Magnaldo I, Pouyssegur J . Serotonin stimulates DNA synthesis in fibroblasts acting through 5-HT1B receptors coupled to a Gi-protein. Nature. 1988; 335(6187):254-6. DOI: 10.1038/335254a0. View

14.

Lanza F, Beretz A, Stierle A, Hanau D, Kubina M, Cazenave J . Epinephrine potentiates human platelet activation but is not an aggregating agent. Am J Physiol. 1988; 255(6 Pt 2):H1276-88. DOI: 10.1152/ajpheart.1988.255.6.H1276. View

15.

van Corven E, Groenink A, Jalink K, Eichholtz T, Moolenaar W . Lysophosphatidate-induced cell proliferation: identification and dissection of signaling pathways mediated by G proteins. Cell. 1989; 59(1):45-54. DOI: 10.1016/0092-8674(89)90868-4. View

16.

Gachet C, Cazenave J, Ohlmann P, Bouloux C, Defreyn G, Driot F . The thienopyridine ticlopidine selectively prevents the inhibitory effects of ADP but not of adrenaline on cAMP levels raised by stimulation of the adenylate cyclase of human platelets by PGE1. Biochem Pharmacol. 1990; 40(12):2683-7. DOI: 10.1016/0006-2952(90)90587-b. View

17.

Defreyn G, Gachet C, Savi P, Driot F, Cazenave J, Maffrand J . Ticlopidine and clopidogrel (SR 25990C) selectively neutralize ADP inhibition of PGE1-activated platelet adenylate cyclase in rats and rabbits. Thromb Haemost. 1991; 65(2):186-90. View

18.

Hourani S, Cusack N . Pharmacological receptors on blood platelets. Pharmacol Rev. 1991; 43(3):243-98. View

19.

MILLS D, Puri R, Hu C, Minniti C, Grana G, Freedman M . Clopidogrel inhibits the binding of ADP analogues to the receptor mediating inhibition of platelet adenylate cyclase. Arterioscler Thromb. 1992; 12(4):430-6. DOI: 10.1161/01.atv.12.4.430. View

20.

Pouyssegur J, Seuwen K . Transmembrane receptors and intracellular pathways that control cell proliferation. Annu Rev Physiol. 1992; 54:195-210. DOI: 10.1146/annurev.ph.54.030192.001211. View